Hegemon Bio co-founder Nathan Skene argues that better target selection for complex genetic traits requires evidence about the cells and DNA-binding events linked to disease. He discusses the gaps in available training data and methods his research team has developed to gather more relevant measurements. The judges ask about cell types, initial indications, data requirements, and brain diseases.
More from the studio
3:12Open MicTechCrunch Disrupt 2026 · AIEEV
AIEEV co-founder Hyeonkyeong (Karen) Kim explains the approach behind Air Cloud: connecting edge GPU devices for AI inference, supporting container-based deployment and autoscaling, and addressing hardware and network security. Recorded at TechCrunch Disrupt 2026.
1:10AI x Bio Pitch Contest
A short look at the September 29 AI x Bio Pitch Contest in San Francisco, from company pitches to the award presentations.
9:25AI x Bio Pitch Contest — Optagon Labs
Khalil Kaddoura presents Optagon Labs' proposed AI-driven loop for drug optimization and lab testing.